Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

5 treatments under study, led by Brexpiprazole

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

3Total
Phase 2/3 (1)
Phase 3 (2)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03620981Phase 2/3CompletedPrimary

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

NCT03724942Phase 3CompletedPrimary

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

NCT02168920Phase 3TerminatedPrimary

Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Showing all 3 trials

Research Network

Common Treatments

  • Brexpiprazole2
  • 6 Mgday1
  • 3 Mgday1
  • 2 Mgday1
  • Placebo 0 Mgday1

Active Sponsors

  • Otsuka Pharmaceutical Co., Ltd.3

Top Investigators

Activity Timeline